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a b s t r a c t
A side effect of the medical improvements of the last centuries is the progressive aging of the world
population, which is estimated to reach the impressive number of 2 billion people with more than 65
years by 2050. As a consequence, age-related diseases, such as heart failure, will affect more and more
patients in the next years. To understand the biological bases of these diseases will be a crucial task in
order to ﬁnd better treatments, and possibly slow age-related morbidity and mortality.
Cardiac stem cells have been at the center of a heated debate and their potential involvement in car-
diac homeostasis has been questioned. In this review, we summarize evidence obtained by independent
groups, on different animal models and humans, that strongly support the important role played by
immature, cardiac resident cells in the cardioprotection against heart failure.
1. Introduction
As a consequence of improvements in reducing perinatal
mortality, treating acute diseases, and ameliorating preventive
medicine, the world population is rapidly aging, so that it has
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been estimated that 2 billion people will be over 65 in 2050 [1].
Biological aging is characterized by a progressive decline of the
abilities to replace cells lost with normal tissue turnover cou-
pled with an impaired ability to respond to a variety of insults,
eventually leading to a condition named frailty. This latter has
been described as a syndrome characterized by decreased reserve
and resistance to stressors, that causes vulnerability to adverse
outcomes. Frailty is not synonymous with comorbidity and dis-
ability. However, comorbidities are a risk factor for frailty and
disabilities are an outcomeof this syndrome [2]. Fromapathophys-
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iological standpoint, frailty is the result of alterations of several
inter-related physiological systems, that lead to a failure in the
function of homeostatic mechanisms [3]. In this regard, the proper
regulation of the complex interaction between poorly differenti-
ated stem/progenitor cell populations residing in adult tissueswith
their specializedmicroenvironment (i.e. stem cell niches) has been
considered to be crucial to generatemature cells adequate in num-
ber and function to provide for tissue homeostasis.
2. Stem cell senescence in aging and age-related
pathologies
2.1. Senescent stem cells accumulate with aging and in
age-related pathologies
Aside fromgerm cells, that constitute a remarkable exception to
cell aging andmayhide the secret for cell rejuvenation, thequantity
of functional somatic stem cells declines with biological aging [4].
This observation supports the “disposable soma” theory of aging,
according towhich the ﬁnitemetabolic resources of each organism
should be optimally located between maintenance and repair of
either its soma or the germline [5]. Since individuals of species that
are protected from those extrinsic causes ofmortality, that occur in
thewild, live beyond their peak of reproductive ﬁtness, phenotypes
of aging and age-related diseases emerge that would not be other-
wise apparent. In line, it can be speculated that, for mutations that
give selective advantages in older ages, beyond the reproductive
age, there is no positive pressure to select enhancedmechanisms of
somatic maintenance [6]. Moreover, organismal maturity has been
associated with a switch between growth promoting to growth
suppressive mechanisms, that leads to a progressive loss of tissue
homeostasis. Speciﬁcally, aging is coupledwith a number of patho-
physiological alterations, such as: a progressive loss ofmusclemass
and function [7], slower wound healing processes [8], defects in
immunity [9], reduced neurogenesis [10], reduced reconstruction
of hair follicle pigmentary unit [11], alterations in vascular struc-
ture and function [12], and a progressive loss of cardiac myocytes
[13]. Intriguingly, a parallel accumulation of cells expressing senes-
cent markers has been observed to occur in tissues with aging,
while the selective clearance of senescent cells prolongs median
lifespan in mice [14]. Cellular senescence is a complex cellular
response to a variety of stressors that is believed to trigger tis-
sue remodeling. Senescent cells are resistant to mitogenic stimuli,
display a permanent growth arrest coupled with a permanently
activated DNA damage response, and release a secretome that is
enriched in pro-inﬂammatory cytokines and matrix remodeling
enzymes (reviewed in [15]). Therefore, a transient induction of cel-
lular senescence, followed by the clearance of senescent cells by
phagocytic cells, is beneﬁcial, since it canpromote tumor regression
or tissue remodeling [16,17].
2.2. Why do senescent and dysfunctional stem cells increase their
frequency with aging?
An accumulating body of literature is showing that, in many
organs, resident stem cells are required for tissue homeostasis
and/or repair after injury. Theobserveddeclineof stemcell function
that ensues with aging has been, therefore, regarded as mechanis-
tic in developing the age relatedpathophysiological alterations that
occur in several tissues.
Deep sequencing experiments have shown that somatic muta-
tions are frequently observed in a large fraction of circulating cells
[18–20]. Consistently, it has been estimated that hematopoietic
stem cells (HSC) accumulate 10 mutations per year [18]. Although
most of these mutations has a neutral effect, part of them is dele-
terious and leads to HSC death or senescence, while others confers
a selective proliferative advantage to the affected HSC. This ﬁnd-
ing has been associated with a progressive collapse of polyclonal
hematopoiesis to a quasi-monoclonal one with aging. In fact, it
has been suggested that every individual with >90years of age has
a single dominant Hematopoietic Stem Cell (HSC) clone generat-
ing the majority of blood cells [6]. Intriguingly, individuals with
clonal hematopoiesis are also characterized by an increased inci-
dence of type 2 diabetes, and of both coronary heart disease and
ischemic stroke [20]. Long term effectsmay arise even as a result of
a correctly repaired DNA damage, since DNA repair may alter DNA
methylationpatterns, andpromotechanges inhistonevariants, his-
tone post-translational modiﬁcations and histone density, leaving
an epigenetic “scar” on chromatin [21]. Consistently, HSC obtained
from aged mice display typical modiﬁcations of epigenetic marks
and, as a consequence, of gene expression patterns, which are
associated with sustained self-renewal and loss of differentiation
[22]. Intriguingly, features of tissue aging coupled with modiﬁca-
tions in gene expression (partially recapitulating those occurring
with aging) have been observed following the controlled induc-
tion of DNA double-strand breaks in vivo [23]. To be mentioned,
genes modulated following DNA damage are enriched in ontology
terms relatedwith inﬂammation, immune response, leukocytepro-
liferation, and chemotaxis [23]. This ﬁnding is reminiscent of the
biologic activity promoted by the modiﬁed secretome released by
senescent cells (i.e. senescence activated secretory phenotype or
SASP). As anticipated and excellently reviewed in [17], the ﬁnal
scope of SASP release is the elimination of senescent cells by inﬁl-
trating leukocytes. Recent ﬁndings, however, indicate that, in the
context of a Pten null background, an immune suppressive SASP is
secreted by senescent cells, which prevents the immune-mediated
ablation of senescent cells [24]. Additionally, aging exerts a pro-
found effect on the immune system, that includes: a skewing of the
hematopoiesis towards themyeloid lineages, and a decrease of NK,
and macrophage cell functions [25]. Therefore, the accumulation
of senescent cells that occurs with aging may be a consequence of
either an immune suppressive SASP or of the reduced function of
key immune cell types that are involved in the removal of senes-
cent cells. This latter event, that may be experimentally inhibited
by means of a pharmacologic or genetic inhibition of immune-
mediated senescent cell disposal, is associated with deleterious
effects, such as: impaired tumor regression [26] or persistent ﬁbro-
sis [27].
2.3. How does an altered environment impacts on stem cell
function and aging?
Age-related changes in stem cell microenvironment (also
known as niche) could limit the reparative performance of this
regenerative pool of cells. Humoral factors and immune cells play
a double role in aging, since they may spread inﬂammation and
promote cell senescence in a paracrine fashion, but are required to
eliminate senescent cells too.
A clear example of the impact exerted by the environment on
stem cell function and tissue aging arises from parabiosis exper-
iments, where the ﬂanks of two animals are sutured in order to
create anastomoses between the two circulatory systems [28].
Early observations demonstrated that ﬂuids and humoral factors
could be exchanged between the parabionts; although a differ-
ence in the transmission of soluble factors was also described (e.g.
steroidal gonadal hormones do not cross the “parabiotic barrier”,
whereas hypophyseal hormones do) [28]. Hematopoietic cells too
are exchanged between the animals, although chimerism requires
seven to ten days of parabiosis in order to reach its maximum [29].
By suturing animals of different ages (i.e. heterochronic parabiosis),
investigators were thus able to demonstrate that blood-borne fac-
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tors could exert both positive and negative effects on age-related
alterations. Speciﬁcally, it was shown that exposure to an aged sys-
temic milieu reduces neurogenesis, hepatocyte proliferation, and
muscle repair (promoting ﬁbrosis). This experimental approach
additionally showed that a converse “rejuvenation” of old tissues
led to improved tissue turnover and healing in the brain, liver and
skeletal muscle [30–32], while it was additionally able to reduce
age-related cardiac hypertrophy [33]. Additionally, heterochronic
cell transplantation experiments performed both in the skeletal
muscle and hematopoietic system have led to the conclusion that
the age of the host, rather than the age of the cell donor, dictates
the efﬁcacy of the treatment [34].
Although these biological effects are largely undisputed, the
mechanisms linked to tissue rejuvenation remain uncompletely
understood and controversial. Among these, it has been shown,
in the skeletal muscle, that the proinﬂammatory cytokine TNF
(that is upregulatedwith aging, in a proinﬂammatory status known
as inﬂammaging) reduces the activation of the Delta1/Notch axis,
which normally occurs in response to injury and is dampenedwith
aging [35,36]. Moreover, the excess of TGF1, that is found in the
serum of aged mice and humans, induces cyclin dependent kinase
inhibition in old muscle stem cells [36]. Wnt signaling, instead,
deserves a special mention. In the skeletal muscle, its activity
is increased both with physiological aging and in the Klotho-
deﬁcient mouse models of accelerated aging [30,37]. Consistently,
serum from aged animals can activate the canonical Wnt pathway,
likely binding to the Frizzled receptors [30], while Wnt16B, that is
secreted by senescent cells (i.e. is a SASP component), can activate
the canonical Wnt/-catenin pathway in vitro [38]. As a result of
the increased Wnt signaling, a myogenic to ﬁbrogenic conversion
of skeletal muscle stem cells has been described [30]. More com-
plex is the impact exerted by Wnt signaling on the cardiovascular
system (we refer the reader to speciﬁc reviews [39,40]), which is
consistent with the dual and stage-speciﬁc role that is played by
this signal transduction pathway during the cardiogenic process.
In fact, although the canonical Wnt signaling promotes the expan-
sionof immature cardiovascularprogenitors, it subsequentlyexerts
an inhibitory effect on cardiomyocyte maturation [41]. To add a
layer of complexity, the age related changes of the cardiac-speciﬁc
Wnt signaling are still controversial, since both an enhanced [42]
and a reduced activation of the pathway have been reported to
occur [43]. Nonetheless, independent studies have demonstrated
the importance of Wnt signaling in promoting repair and ﬁbrosis
followingmyocardial injury, possibly acting on cardiac progenitors
[44,45]. Intriguingly, Wnt is inhibited by the Hippo/YAP pathway
[46], an integrator of biochemical and biophysical stimuli that may
be altered by aging and pathologic conditions [47].
With regard to neural stem cells, it has been shown that
the proinﬂammatory chemokine CCL11 increases with aging and
impairs neurogenesis in mice [31].
A more heated debate and controversy surrounds the role of
Growth Differentiation Factor (GDF) 11 in aging. This latter is a
member of TGF family,which shares a 90% sequence identitywith
the mature form of GDF8 (also known as myostatin), that has been
shown, in recent reports, to decrease with age [33,48,49]. A series
of seminal studies has shown that supplementing old mice with
GDF11may reverse age-related cardiac hypertrophy, could restore
the functional impairment of skeletal muscle stem cells, improve
cerebral vasculature, and enhance neurogenesis [33,48,50]. How-
ever, these data were recently challenged by other reports that
showed that, as opposed towhat previously reported, GDF11 levels
increase with age [51,52]. Furthermore, data from different labora-
tories indicate that GDF11 does not stimulate or could even inhibit
skeletal muscle regeneration [51,53]. These conﬂicting reports,
however could only denote the complexity of GDF11 effects in the
body. In line, the claimed beneﬁcial effects of GDF11 on the brain
have not been confuted yet [54].
An important player, that could be responsible for the beneﬁcial
effects of parabiosis, is the immune system. Indeed, following acute
muscle injury, both pro-inﬂammatory (M1) and anti-inﬂammatory
(M2) macrophages inﬁltrate the damaged area, and exert dis-
tinct, but integrated roles in promoting skeletal muscle repair
[55]. Although, it should be acknowledged that the description of
macrophage activation is still confusing andamatter of debate [56],
regulatory T cells (Treg), that are attracted to the injured area by
IL-33 [57], promote tissue repair both by regulatingM1–M2 switch,
and releasing growth-promoting factors that stimulate satellite
cells [58]. During aging, the reduced capacity for muscle repair
is coupled with a reduced capacity of Treg to accumulate in sites
of tissue damage. This condition may be reversed by IL33 supple-
mentation [57]. We consider these ﬁndings of particular relevance,
since it has been recently shown that mesenchymal stem cell ther-
apy increases the frequency of reparative M2 macrophages in the
infarcted myocardium [59]. Moreover, macrophages were shown
to be essential both for: healing and repair of acute myocardial
infarction in the adult mammalian heart [59], and for the regen-
eration of the neonatal mouse heart [60]. Intriguingly, the plasma
concentrations of soluble ST2 (a decoy receptor for IL33, that is
induced when a mechanical strain is imposed to cardiomyocytes
and ﬁbroblasts) are associated with increased risk for cardiovascu-
lar mortality, in patients with acute and chronic heart failure, and
even in the low-risk, population-based cohort of the Dallas Heart
Study [61].
Last, a relatedmechanism that could inﬂuence the immune sys-
tem, is the bioavailability of trace elements, such as copper (Cu)
and zinc (Zn). Indeed, the Cu to Zn ratio (CZr) is incremented in
acute inﬂammation, increases as a function of age, and is associ-
ated with the risk of cardiovascular disease death [62]. As recently
suggested, inﬂammaging and the SASP released by senescent cells
may be involved in raising CZr levels [62]. Importantly, Zn deﬁ-
ciency is associated with reduced polymorphonuclear chemotaxis
and decreased phagocytosis. Additionally, Zn promotes monocyte
adhesion and is important for the production of pro-inﬂammatory
cytokines, increases the differentiation of CD34+ cells toward NK
cells and increasesNK cytotoxicity. Altogether, these functions sug-
gest that Zn deﬁciency may be associated with a defective ability
of the immune system to clear senescent cells [63].
3. (Stem) cell senescence in heart failure
3.1. Role of stem cells in the turnover of post-natal
cardiomyocytes
Although we are still far away from an unambiguous quantiﬁ-
cation of the cardiac turnover, the evidence that cardiac myocytes
can be generated postnatally has been nowadays accepted and
is no longer viewed as heresy [64,65]. Moving from a large body
of literature showing that mature cardiomyocytes are withdrawn
from the cell cycle soon after birth [66,67], several independent
investigators have hypothesized that, in analogy with what has
been described for other tissues, including the skeletalmuscle [68],
resident, undifferentiated stem/progenitor cells could be respon-
sible for the observed adult myocyte turnover. In support to this
hypothesis, elegant genetic labeling experiments, that took advan-
tage of theMHC-MerCreMer x Z/EGmousemodel to permanently
label cardiomyocytes before injury [69], have repeatedly shown the
contribution of immature cells to myocyte replacement [69–71].
These ﬁndings were consistent with earlier ones, which described
cardiomyocyte chimerism in recipients of sex-mismatched car-
diac transplants [72,73]. However, to inﬂame the debate, more
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recent ﬁndings from Lee’s laboratory, using the same animalmodel
they employed before [65,69,71], have subsequently claimed that
a subset of adult cardiomyocytes would be responsible for car-
diomyocyte renewal [65]. Nonetheless, in almost 15 years of work,
several laboratories worldwide have independently shown that
cells with stem/progenitor properties reside in the myocardium
of mammalians, including humans, and may generate cardiomy-
ocytes, smooth muscle cells, endothelial cells, and ﬁbroblasts both
in vitro and in vivo (reviewed in [74–76]). Cardiac primitive cells
were thus isolated and cultured on the basis of different antigenic
proﬁles and protocols (e.g. c-Kit, Sca1, PDGFR, cardiospheres)
[74–76]. Of these, cKit expressing cells have been at the center of
an intense debate. In fact, while Ellison and coll. have shown that:
cKit+ cells promote the spontaneous wave of myocardial regener-
ation that is observed following isoproterenol infusion, in a mouse
model of Takotsubo cardiomyopathy, while ablation of cKit+ cells
impairs myocardial repair [70], other reports, that employed lin-
eage tracking experiments, have been considered as a deﬁnitive
proof against the stem cell nature of cKit expressing cells [77].
We will not address technical issues and difference in data inter-
pretation that may have led investigators to draw this conclusion
and refer the reader to two commentaries [78,79]. However, we
should point out that, as suggested by Hatzistergos and Hare, 4
independent genetic studies have demonstrated the presence of
cKit+ cardiomyogenic progenitors in the embryonic and postnatal
mouse hearts [78]. However, according to Hatzistergos and coll.,
bonemorphogenetic protein signalingmay restrict the cardiomyo-
genic potential of cKit+ cells, suggesting that external inﬂuences
may limit the cardiomyocyte differentiation of cells that have the
potency to do so (in line with the principles of potentiality and
actuality, already introduced by Aristotle around 300 B.C.) [80].
Accordingly, several reports have demonstrated that the beneﬁ-
cial effect of cardiac cell therapy may result from the ability of
implanted cells to unlock the endogenous potential to repair [81].
Published results from a collaboration between us and Madeddu’s
lab have shown that the stimulation of cardiomyocyte proliferation
from endogenous sources, togetherwith the protection of ischemic
cardiomyocytes from apoptotic cell death, are a potentmechanism
of action of human cardiac stemcells [82,83]. Intriguingly, the exact
mechanism of paracrine action of cardiac progenitors has not been
fully identiﬁed yet, but may involve actors (i.e. miRNAs and exo-
somes) able to target with one hit multiple molecular pathways in
target cells [84,85].
3.2. (Stem) cell senescence is associated with aging and
age-related pathologies
The progressive decline of the ability to adequately maintain
tissue homeostasis or to repair tissues after injury is associated
with the occurrence of age-related diseases (such as heart failure,
HF) and, eventually, with frailty [15]. As summarized in Fig. 1, we
and other authors have tested the hypothesis that the progressive
accumulation of dysfunctional and senescent stem cells (and their
differentiated progeny) plays a crucial role in the pathogenesis of
cardiac aging andHF. Several lines of evidence seem to support this
view. Since it has been postulated [76] and experimentally shown
that different cardiac resident stem cell populations show a large
degree of gene expression overlap [86], we will discuss evidence
of resident stem cell senescence, not distinguishing between the
different (sub)populations of primitive cells.
Senescent primitive cells and cardiomyocytes accumulate in
the myocardium of aged patients with severe systolic dysfunc-
tion, in the absence of a history suggestive of ischemia, diabetes,
hypertension, valvulopathy or myocarditis [87]. Additionally, his-
tological and morphometric data suggested that patients affected
by HF secondary to chronic ischemia were characterized by the
accumulation of senescent stem cells in the left ventricle [88]. This
ﬁnding prompted us to isolate, propagate in culture and analyze
cardiac primitive cells both from recipients of cardiac transplanta-
tion, affected by end stage HF, and from normal, donated hearts.
Histological and in vitro studies showed that both aging and heart
failure deplete human atria of primitive cells. Furthermore, age and
pathology increased the rate of cardiac stem cell senescence and
dysfunction, reducing thier proliferative, migratory and differen-
tiation abilities [82,89,90]. In line, Cossu and coll. demonstrated
the reduced clonogenicity and differentiation capacity of primi-
tive cells isolated from the heart of patients affected by mitral and
aortic regurgitation with ensuing cardiac hypertrophy [91]. With
regard to comorbidities, diabetes too, a relevant age-related dis-
ease, impairs the in vitro proliferative and differentiation capability
of resident stem cells, further accelerating their senescence even
when compared with ischemic, non diabetic patients [92]. Last,
anthracyclin based chemotherapy, a condition that hasbeenassoci-
atedwith accelerated aging [93] andHF, is characterized by cardiac
progenitor cell senescence [94].
3.3. Is stem cell senescence good for the heart?
Although the association between stem cell senescence and
HF has been repeatedly proven, recent data and a provocative
review article of Mun˜oz-Espín and Serrano [16] have suggested
that the accumulation of senescent ﬁbroblasts that is observed
aftermyocardial infarctionmay indeed be beneﬁcial, since itwould
limit cardiac ﬁbrosis [95]. Nonetheless, while an acute induction of
cell senescence may be required to stimulate regeneration (as sug-
gested in the same review [16]), an increasing level of evidence
indicates that the persistence of senescent stem cells limits car-
diac repair and may lead to HF. In line, the selective clearance of
senescent, p16InkA positive, cells that accumulate in mouse tissues
(including the heart) with aging is associated with a reduction of
cardiac hypertrophy, and an increased resistance of the heart to
-adrenergic stress [14].
With regard to the speciﬁc involvement of cardiac resident
stem cells in tissue repair, Ellison and coll. have demonstrated
that the selective ablation of cKit+ cells reduces the ability of
acutely injured hearts to recover [79]. In line with these data,
focusing on anthracyclin cardiomyopathy, DeAngelis and coll. have
recently observed that, while the direct injection of healthy cardiac
stem cells improves the cardiac function and anatomy of Doxoru-
bicin (DOXO) treated rats, senescent cardiac stem cells, that were
exposed to DOXO before in vivo administration, did not promote
myocardial repair in the same animal model [94].
Focusing on the molecular mechanisms associated with car-
diac stem cell dysfunction, independent groups have additionally
shown that biological aging and diabetes are coupled with a
reduced expression of the serine/threonine kinase Pim1 [96,97].
Importantly, the forced expression of this protein reversed car-
diacdysfunctionanddiminished the frequencyof senescent cardiac
primitive cells [96,97]. Pim1 regulates the expression of nucle-
ostemin (a stem cell-related nucleolar protein required for cell
cycle progression and proliferation, that is downregulated follow-
ing differentiation) via cMyc. Intriguingly, aging and replicative
senescence are associated with a progressive loss of nucleostemin
expression, while mice that are haploinsufﬁcient for nucleostemin
are characterized by an accelerated cardiac remodeling leading
to HF, coupled with cell senescence [98]. To further advance
our understanding of the mechanisms coupled with stem cell
senescence and dysfunction in HF, we took advantage of gene
expression proﬁling and biostatistical analysis of genes differen-
tially expressed between cardiac resident stem cells cultured from
normal organs vs. failing hearts [82,89,90]. With this approach,
we have shown that the hyperactivation of the TORC1 com-
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Fig. 1. Involvement of stem cell senescence in aging and heart failure. Cartoon summarizing the experimental evidence, collected both on animal models and humans,
indicating the involvement of cardiac stem cells in cardiac pathology. The function, activation, and senescence of cardiac resident stem cells was evaluated in mice, rats, and
humans. Speciﬁcally, mouse and rat models of drug induced injury (i.e. isoproterenol, doxorubicin or streptozotocin administration to mimic Takotsubo cardiomyopathy,
chemotherapy induced cardiomyopathy or type 1 diabetes, respectively), aged mice, and mice heterozygous for the expression of nucleostemin were studied. Samples of
donated and explanted human hearts collected after cardiac transplantation were analyzed as well. Histologically, cardiac remodeling is characterized by hypertrophy of
cardiomyocytes (depicted in red), ﬁbrosis (shown in cyan), and by the accumulation of cardiac resident stem cells (labeled in green) that express senescent markers (labeled
in pink). Takotsubo-like cardiomyopathy, induced by the acute administration of isoproterenol, is characterized by acute cell injury and death (yellow labeling of nuclei),
inﬂammatory cell inﬁltration, and by cardiac stem cell activation.
Table 1
Experimental interventions of “rejuvenation” that have been reported in the literature.
Type of
intervention
Intervention modality Mechanism of action Reference
Systemic intervention Genetic ablation of p16INK4A
positive cells (i.e. senolytic
approach).
Activation of a drug inducible suicide
transgene (i.e. INK-ATTAC) that becomes
activated in senescent cells.
[14,101]
Pharmacological removal of
senescent cells (i.e. use of senolytic
drugs).
Inhibition of prosurvival, anti-apoptotic
pathways in senescent cells (e.g. by
dasatinib, quercetin, navitoclax, and
TW-37)
[99,102]
Restoration of a “youthful”
microenvironment.
Administration of systemic factors (e.g.
GDF11, oxytocin or BPIFB4) or inhibition of
pathways altered with aging (e.g. TGF or
Wnt). However, the impact of these
interventions on cardiovascular system
rejuvenation is still speculative or unclear.
[33,103–106]
Cell therapy Administration of young, healthy
stem cells to a diseased heart.
Protection from cardiomyocyte senescence
and improved cardiac repair.
[82,83,107]
Ex vivo rejuvenation of
reparative cells
In vitro pharmacologic
pre-treatment of stem cells
isolated from old, diseased animals
followed by their in vivo delivery.
Inhibition or activation of pathways that
are modiﬁed by the aging process (e.g.
inhibition of mTOR signaling, Sirt1
activation).
Use of epigenetic drugs able to revert, at
least partially, the alterations that are
associated with systemic diseases (e.g.
diabetes).
[82,92,94]
Genetic modiﬁcation of stem cells
to enhance their function.
Overexpression of either the prosurvival
kinase Pim-1 or nucelostemin to reverse
cellular senescence. Overexpression of
CAMKIIB to enhance stress resistance.
[97,98,108]
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plex, coupled with altered proteostasis, and a dysfunction of the
autophagy/lysosome pathway are central players leading to car-
diac stem cell dysfunction. Importantly, these alterations can be
reversedbymeansof apharmacological treatment, that reduces the
frequencyof senescent stemcells and restores the in vivo reparative
properties of cardiac stem cells [82]. In line with our data, Vecellio
and coll. have recently demonstrated that the altered function of
cardiac resident stem cells isolated fromdiabetic patients is associ-
atedwith amodiﬁed epigenetic landscape. Importantly, epigenetic
interventions could reverse these alterations in vitro [94]. Last, acti-
vation of the class III histone deacetylase Sirt1 was able to prevent
the senescence of cardiac stem cells exposed to doxorubicin, par-
tially restoring their in vivo reparative properties [94].
4. Cardiac rejuvenation
Given these premises, several investigators have tried to restore
cardiac structure and function with different strategies that have
been collectively named cardiac “rejuvenation”.
As summarized in Table 1, the experimental approaches could
be broadly classiﬁed into four distinct groups: organism rejuvena-
tion by means of systemic interventions, cardiac rejuvenation by
means of cell therapy, and ex vivo rejuvenation of reparative cells.
Among these interventions, the identiﬁcation of senolytic drugs,
able to clear senescent cells inducing their apoptosis is certainly
one of the most exciting areas of investigation [99]. It is tempt-
ing to speculate that this approach will be translated to the clinic,
especially if it will combine in vitro screening assays on relevant
cell types, such as cardiac progenitors cultured fromhuman cardiac
biopsies, with appropriate animal models [100].
5. Conclusion
Aging and heart failure are associated with a progressive accu-
mulation of senescent tissue resident cardiac stem cells. The
mechanisms that lead to this outcome are part cell intrinsic, part
due to systemic changes associated with organism aging. A heated
debate has questioned the role of resident stem cells in tissue
homeostasis and the causative role of the persistence of senescent
cells in cardiac dysfunction. In this review,we have brieﬂy reported
data from a large number of studies, obtained from different labo-
ratories, on independent animal models (including humans), that
support the notions that: resident stem cells sustain cardiac repair
after damage; aging and HF are coupled with the accumulation
of epigenetic, gene expression, and biological changes of cardiac
resident stem cells that accelerate their senescence rate, impair-
ing their protective function. Finally, and most importantly, we
have understood that the alterations imposed on resident cells by
pathology are not irreversible, but could be reversed by pharmaco-
logical therapy, opening the possibility of employing patient-based
cellularmodels to better tailor cardioprotective drugs, able to stim-
ulate the primitive cell compartment.
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